Infectious diseases continue to dominate global health threats: major contributor to global mortality and morbidity dominating WHO’s 2019 list of health threats and amplified by recent coronavirus outbreak.
Trusted and proven technology with third party validation: Genetic Signatures have achieved 100% customer retention since 2016 and the accuracy of the technology has been clinically validated.
COVID-19 pandemic creating new opportunities for global expansion: increasing international recognition through the EasyScreenTM SARS-CoV-2 launch creates new avenues to expand customer base.
On track to achieve multiple commercial milestones in 2020: international interest bolstered by the SARS-CoV-2 product release creates a platform for new contract wins for broader EasyScreenTM products.
Attractive and scalable revenue model: highly scalable business model with favourable unit economics expected to underpin growth through FY20 and beyond.
Competitive advantage underpinned by novel 3baseTM technology:resistant to genetic mutations in the micro-organisms, and implemented in a simplified workflow processes, increasing throughput capacity, reducing time to results and creating cost saving benefits
Be the first to comment